Results of the pivotal Spyral-HTN OFF MED study presented at the American College of Cardiology's Annual Scientific Session on March 29 demonstrated significant reduction in blood pressure three months after renal denervation (RDN) in patients with unmedicated hypertension.

Fractyl Laboratories Inc. has released data from a mixed meal tolerance study that shows its procedure for resurfacing the duodenal mucosa improves fasting blood glucose and reduces liver fat.

HONG KONG – Phase II data of South Korea-based Qurient Co. Ltd.’s novel antibiotic candidate may offer hope that the first universal regimen to treat tuberculosis (TB) regardless of drug resistance status has been found.

During the conference call on earnings in March, CEO Dror Harats told investors that “the most important thing” about VBL Therapeutics Ltd.’s then-upcoming analysis of interim phase III data with gene therapy VB-111 (ofranergene obadenovec) is that it was “designed in a way that will enable us to tell the market if we are at least as good as what we've seen” in the phase II experiment.

DUBLIN – The Genentech arm of Roche Holding AG plans to move its interleukin-6 inhibitor, Actemra, into a global phase III trial in patients with severe pneumonia associated with COVID-19 infection.

HONG KONG – Korean biopharma Celltrion Inc. said it’s halfway through the process of creating a super antibody to reign in the COVID-19 novel coronavirus that has claimed almost 13,000 lives globally.